PT - JOURNAL ARTICLE AU - Hippisley-Cox, Julia AU - Clift, Ash K. AU - Coupland, Carol AU - Keogh, Ruth AU - Diaz-Ordaz, Karla AU - Williamson, Elizabeth AU - Harrison, Ewen M. AU - Hayward, Andrew AU - Hemingway, Harry AU - Horby, Peter AU - Mehta, Nisha AU - Benger, Jonathan AU - Khunti, Kamlesh AU - Speigelhalter, David AU - Sheikh, Aziz AU - Valabhji, Jonathan AU - Lyons, Ronan A. AU - Robson, John AU - Semple, Calum AU - Kee, Frank AU - Johnson, Peter AU - Jebb, Susan AU - Williams, Tony AU - Coggon, David TI - Protocol for the development and evaluation of a tool for predicting risk of short-term adverse outcomes due to COVID-19 in the general UK population AID - 10.1101/2020.06.28.20141986 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.28.20141986 4099 - http://medrxiv.org/content/early/2020/06/29/2020.06.28.20141986.short 4100 - http://medrxiv.org/content/early/2020/06/29/2020.06.28.20141986.full AB - Introduction Novel coronavirus 2019 (COVID-19) has propagated a global pandemic with significant health, economic and social costs. Emerging emergence has suggested that several factors may be associated with increased risk from severe outcomes or death from COVID-19. Clinical risk prediction tools have significant potential to generate individualised assessment of risk and may be useful for population stratification and other use cases.Methods and analysis We will use a prospective open cohort study of routinely collected data from 1205 general practices in England in the QResearch database. The primary outcome is COVID-19 mortality (in or out-of-hospital) defined as confirmed or suspected COVID-19 mentioned on the death certificate, or death occurring in a person with SARS-CoV-2 infection between 24th January and 30th April 2020. Our primary outcome in adults is COVID-19 mortality (including out of hospital and in hospital deaths). We will also examine COVID-19 hospitalisation in children. Time-to-event models will be developed in the training data to derive separate risk equations in adults (19-100 years) for males and females for evaluation of risk of each outcome within the 3-month follow-up period (24th January to 30th April 2020), accounting for competing risks. Predictors considered will include age, sex, ethnicity, deprivation, smoking status, alcohol intake, body mass index, pre-existing medical co-morbidities, and concurrent medication. Measures of performance (prediction errors, calibration and discrimination) will be determined in the test data for men and women separately and by ten-year age group. For children, descriptive statistics will be undertaken if there are currently too few serious events to allow development of a risk model. The final model will be externally evaluated in (a) geographically separate practices and (b) other relevant datasets as they become available.Ethics and dissemination The project has ethical approval and the results will be submitted for publication in a peer-reviewed journal.Strengths and limitations of the studyThe individual-level linkage of general practice, Public Health England testing, Hospital Episode Statistics and Office of National Statistics death register datasets enable a robust and accurate ascertainment of outcomesThe models will be trained and evaluated in population-representative datasets of millions of individualsShielding for clinically extremely vulnerable was advised and in place during the study period, therefore risk predictions influenced by the presence of some ‘shielding’ conditions may require careful considerationCompeting Interest StatementJHC reports grants from National Institute for Health Research Biomedical Research Centre, Oxford, grants from John Fell Oxford University Press Research Fund, grants from Cancer Research UK (CR-UK) grant number C5255/A18085, through the Cancer Research UK Oxford Centre, grants from the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z), during the conduct of the study. JHC is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health who supply the QResearch database used for this work. JHC is a founder and shareholder of ClinRisk ltd and was its medical director until 31st May 2019. ClinRisk Ltd produces open and closed source software to implement clinical risk algorithms (outside the proposed work) into clinical computer systems. CC reports receiving personal fees from ClinRisk Ltd., outside this work. KK reports grants from NIHR, is the National Lead for ethnicity and diversity for the National Institute for Health Applied Research Collaborations, and Director of the University of Leicester Centre for Black Minority Ethnic Health. AH reports being a member of the New and Emerging Respiratory Virus Threats Advisory Group. PJ reports employment by NHS England during the conduct of the study, grants from Epizyme, Janssen, personal fees from Takeda, Bristol-Myers-Squibb, personal fees from Novartis, Celgene, Boehringer Ingelheim, Kite Therapeutics, Genmab, and Incyte, all outside the submitted work. AKC reports personal fees from Huma Therapeutics, outside of the scope of the submitted work. RL reports grants from Health Data Research UK outside the submitted work. AS reports grants from MRC during the conduct of the study. CS reports grants from the DHSC National Institute of Health Research UK, Medical Research Council UK, and the Health Protection Unit in Emerging and Zoonotic Infections (University of Liverpool) during the conduct of the study, and is a minority owner in Integrum Scientific LLC (Greensboro, NC, USA) outside of the submitted work. RHK, JB, KDO, JR, NM, EW, EH, HH, PH, DS, JV, FK, SJ, TW and DC have no conflicts of interests to declare.Funding StatementThis work will be funded by a grant from the National Institute for Health Research. QResearch receives NIHR Oxford Biomedical Research Centre; the Medical Sciences Division of the University of Oxford; John Fell Oxford University Press Research Fund; the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z); Cancer Research UK (CR-UK) grant number C5255/A18085, through the Cancer Research UK Oxford Centre. It also receives contributions in kind from EMIS Health (commercial supplier of NHS health computer systems). KC is supported by the British Heart Foundation (CH/16/1/32013). RHK is supported by a UKRI Future Leaders Fellowship (MR/S017968/1) KDO is supported by a Royal Society-Wellcome Trust Sir Henry Dale Fellowship 218554/Z/19/Z). KK is supported by National Institute for Health Research Applied Research Collaboration East Midlands (NIHR ARC-EM) and the NIHR Leicester Biomedical Research Centre. AS is supported by Health Data Research UK (MR/R008345/1) and the Medical Research Council (MR/R008345/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:East Midlands - Derby Research Ethics Committee 18/EM/0400All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTo guarantee the confidentiality of personal and health information only the authors have had access to the data during the study in accordance with the relevant licence agreements. Access to the QResearch data is according to the information on the QResearch website (www.qresearch.org). The equations presented in this paper will be released as Open Source Software under the GNU lesser GPL v3 to ensure transparency and wide availability. The open source software allows use without charge.